Related Experiment Video
Updated: Jun 12, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Biomarkers in lung cancer
Alessandra Bearz1, Massimiliano Berretta, Alessandro Cappellani
1Department of Medical Oncology, CRO-IRCCS, National Cancer Institute, Aviano, PN, Italy. abearz@cro.it
Frontiers in Bioscience (Elite Edition)
|June 3, 2010
Summary
Biomarkers, once overlooked, are now vital in lung cancer management. They increasingly guide treatment decisions and offer prognostic insights for patients.
Area of Science:
- Oncology
- Biomarker Research
- Clinical Management
Background:
- Historically, tissue and circulating biomarkers were deemed ineffective for lung cancer prognosis and treatment prediction.
- Recent advancements have shifted this perspective, highlighting their growing importance.
Purpose of the Study:
- To review the evolving role of tissue and circulating biomarkers in lung cancer management.
- To emphasize their transition from ineffective tools to crucial predictive and prognostic indicators.
Main Methods:
- Literature review of studies on biomarkers in lung cancer.
- Analysis of current clinical practices and emerging research.
Main Results:
- Biomarkers are now recognized as essential for predicting treatment response in lung cancer.
- They are increasingly utilized to guide personalized therapy selection.
- Biomarkers also show potential for improving prognostic assessments.
Conclusions:
- Tissue and circulating biomarkers are indispensable in modern lung cancer management.
- Their predictive capabilities are transforming therapeutic strategies.
- Further research is expected to solidify their prognostic value.